1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

Technology appraisal guidance [TA425] Published: 21 December 2016

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 227 KB 23 January 2017  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document PDF 376 KB 17 November 2016  
  • Committee papers PDF 1.17 MB 17 November 2016  

Invitation to participate

  • Final scope PDF 101 KB 19 July 2016  
  • Final matrix PDF 96 KB 19 July 2016  

Appeal

  • Appeal  
  • : Appeal letter PDF 1.41 MB 02 September 2011  
  • : Scrutiny letter PDF 270 KB 12 September 2011  
  • : Appeal letter PDF 741 KB 20 October 2017  
  • : Response to scrutiny letter PDF 504 KB 26 September 2011  
  • : Appeal letter PDF 316 KB 29 August 2011  
  • : Final scrutiny letter PDF 223 KB 29 September 2011  
  • : Scrutiny letter PDF 249 KB 12 September 2011  
  • : Response to scrutiny letter PDF 419 KB 21 September 2011  
  • : Appeal letter PDF 257 KB 20 October 2017  
  • : Final scrutiny letter PDF 279 KB 30 September 2011  
  • : Response to scrutiny letter PDF 1.76 MB 03 October 2011  
  • Appeal decision TA241 & TA251 PDF 236 KB 30 January 2012  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document TA241 PDF 306 KB 11 August 2011  
  • Committee papers TA241 PDF 3.76 MB 11 August 2011